Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Orbital Disease Clear all
Completed Phase 3 Interventional

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

NCT05517421
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Batoclimab, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
29
States / cities
Beverly Hills, California • Carlsbad, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jul 23, 2026, 5:19 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction

NCT06275373
View directory record Official record
Conditions
Thyroid Eye Disease, Graves Ophthalmopathy, Graves Disease
Interventions
Teprotumumab Injection [Tepezza]
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Jul 23, 2026, 5:19 AM EDT
Recruiting Phase 2Phase 3 Interventional

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

NCT06112340
View directory record Official record
Conditions
Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto
Interventions
linsitinib
Drug
Lead sponsor
Sling Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Miami, Florida • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Jul 23, 2026, 5:19 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT06727604
View directory record Official record
Conditions
Graves' Disease
Interventions
IMVT-1402, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
64
States / cities
Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

NCT01868997
View directory record Official record
Conditions
Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Interventions
teprotumumab, normal saline
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Jul 23, 2026, 5:19 AM EDT
Completed No phase listed Observational

Computer Modeling With Reconstruction of Maxillofacial Skeleton

NCT00583856
View directory record Official record
Conditions
Maxillofacial Injury
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
11 Years to 50 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2010 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study

NCT03461211
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Teprotumumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Beverly Hills, California • Los Angeles, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Jul 23, 2026, 5:19 AM EDT
Terminated No phase listed Observational

Efficacy of Methimazole Dosing Algorithm

NCT05964452
View directory record Official record
Conditions
Graves Disease
Interventions
Methimazole Tablets
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jul 23, 2026, 5:19 AM EDT
Withdrawn Not applicable Interventional

The Use of Prophylactic Antibiotics in Isolated Blowout Fractures

NCT01504568
View directory record Official record
Conditions
Orbital Fractures, Orbital Cellulitis
Interventions
Treatment
Other
Lead sponsor
University of Arkansas
Other
Eligibility
5 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2012 · Synced Jul 23, 2026, 5:19 AM EDT
Withdrawn Phase 4 Interventional

The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.

NCT01927406
View directory record Official record
Conditions
Thyroid Eye Disease, Ocular Hypertension, Glaucoma
Interventions
Prostaglandin Analog, Timolol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Jul 23, 2026, 5:19 AM EDT
Not yet recruiting No phase listed Observational

Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM)

NCT07623837
View directory record Official record
Conditions
Ocular Motility Disorders, Strabismus, Extraocular Muscle Dysfunction, Thyroid Eye Disease
Interventions
Glandy EOM (AI-based quantitative eye movement analysis software)
Device
Lead sponsor
THYROSCOPE INC.
Industry
Eligibility
22 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Not applicable Interventional

Shared Decision Making in Graves Disease - Graves Disease (GD) Choice

NCT02107794
View directory record Official record
Conditions
Graves' Disease, Thyroid Disease, Hyperthyroidism
Interventions
Decision Aid
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Jul 23, 2026, 5:19 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

NCT05276063
View directory record Official record
Conditions
Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto
Interventions
Linsitinib, Placebo
Drug
Lead sponsor
Sling Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Jul 23, 2026, 5:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exploring Accessible Beauty for Individuals With Upper Extremity Deficits

NCT05945784
View directory record Official record
Conditions
Stroke, Ischemic, Stroke Hemorrhagic, Stroke (CVA) or TIA, Stroke, Acute, Traumatic Brain Injury, SCI - Spinal Cord Injury, Ehlers-Danlos Syndromes (EDS), Lupus Erythematosus, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Amyotrophic Lateral Sclerosis, Graves Disease, Muscular Dystrophies
Interventions
Use of Rare Beauty makeup products
Other
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Jul 23, 2026, 5:19 AM EDT
Terminated No phase listed Observational

B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease

NCT02316691
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Jul 23, 2026, 5:19 AM EDT
Completed No phase listed Observational Results available

Coronary Flow Reserve Following Orbital Atherectomy

NCT02339545
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary Orbital Atherectomy plus Stenting
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Chandler, Arizona • Coon Rapids, Minnesota • Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Jul 23, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Radioactive Iodide Therapy for Pediatric Graves' Disease

NCT01269749
View directory record Official record
Conditions
Graves' Disease
Interventions
RAI treatment, ATD Group
Radiation · Drug
Lead sponsor
University of Florida
Other
Eligibility
Up to 18 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Gainesville, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 23, 2026, 5:19 AM EDT
Terminated Phase 3 Interventional

Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

NCT05517447
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Observational cohort study, Batoclimab
Other · Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Glendora, California • Aurora, Colorado • Livonia, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 23, 2026, 5:19 AM EDT
Terminated Phase 3 Interventional

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.

NCT06307626
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Mission Hills, California • Rancho Cordova, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 23, 2026, 5:19 AM EDT
Recruiting Phase 2 Interventional

An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease

NCT07438405
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
AMG 732
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Little Rock, Arkansas • Kissimmee, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 5:19 AM EDT
Terminated Phase 3 Interventional Results available

Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?

NCT04080505
View directory record Official record
Conditions
Graves Disease
Interventions
SSKI- Potassium Iodide
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 5:19 AM EDT
Active, not recruiting Phase 3 Interventional

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

NCT06812325
View directory record Official record
Conditions
Thyroid Eye Disease (TED)
Interventions
VRDN-003, Placebo
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
32
States / cities
Tuscon, Arizona • Inglewood, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 5:19 AM EDT
Recruiting Phase 1 Interventional

Study of BHV-1300 in Graves' Disease

NCT06980649
View directory record Official record
Conditions
Graves Disease
Interventions
BHV-1300
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
South Gate, California • Miami, Florida • Columbus, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 5:19 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

NCT07570316
View directory record Official record
Conditions
Graves' Disease, Graves Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
16
States / cities
Orange, California • Pasadena, California • Fleming Island, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 5:19 AM EDT